Oncolytic myxoma virus and engineering strategies for advanced cancer immunotherapy
Trujillo Yeriomenko AD., Isaeva AS., Idota EE., Zhivoderov SP., Yurkov SG., Malogolovkin AS.
Clinical Trial, published in iScience (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- iScience (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42181227
- PMCID
- PMC13194175
- DOI
- 10.1016/j.isci.2026.115812
Abstract (original English)
In cancer immunotherapy, oncolytic viruses (OVs) offer an alternative approach to kill malignant cells by inducing cancer-specific host immune system activation. Given the ongoing need for safe and effective viral vectors for immunotherapy, non-zoonotic animal viruses have attracted significant interest. Here, we review the oncolytic myxoma virus (MYXV) and emphasize its emerging role in cancer immunotherapy. We critically discuss recent advances in cancer therapy using MYXV, primarily focused on engineered viral modifications. Furthermore, we briefly review alternative delivery strategies for MYXV and its combination with other anticancer agents. We also compare several key features of MYXV with those of other well-characterized OVs. In this study, we explore the key preclinical milestones that must be achieved for the MYXV OV to successfully transition to clinical trials. Preclinical studies have indicated the promising oncolytic potential and satisfactory safety profile of MYXV, thus paving the way for human clinical trials.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.